Dean J. Mitchell - 12 Jun 2026 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: Director
Issuer ticker: TBPH
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2026, 21:37:40 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Dean J. Mitchell filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 16 Jun 2026.

Key facts

This page summarizes Dean J. Mitchell's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2026, 21:37.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001199297 Primary reporting owner

MITCHELL DEAN J

Relationship: Director
Address: C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Signature date: 16 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Award

Transaction value
Shares: +6,009
Change %: +6.6%
Price: $0.000000^*
Shares after: 97,213
Date: 12 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBPH transaction Derivative

Share Option (Right to Buy)

Award

Transaction value
Shares: +13,398
Change %
Price: $0.000000^*
Shares after: 13,398
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 13,398
Exercise price: $16.64
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.